Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 901–1,000 of 1,001
Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis
Kajita, K., Ishii, I., Mori, I., Asano, M., Fuwa, M., & Morita, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020932 · Cited by 33
“In patients with T2DM, the blockade of IL-1 receptor signaling improves glycemic control and the ability to secrete insulin, but not insulin resistance itself, as evaluated by insulin-regulated gene expression in skeletal muscle and serum adiponectin levels [63].”
BackgroundObesity, Inflammation, and Insulin Resistance
Ellies, L. G., Johnson, A., & Olefsky, J. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6819-6_1 · Cited by 32
Zhang, X.-M., Guo, L., Chi, M., Sun, H., & Chen, X.-W. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0512-5 · Cited by 31
Verma, G., Bhatia, H., & Datta, M. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-12-0885 · Cited by 32
Regenerative Therapies for Diabetic Microangiopathy
Bassi, R., Trevisani, A., Tezza, S., Nasr, M. B., Gatti, F., Vergani, A., Farina, A., & Fiorina, P. (2012) · Experimental Diabetes Research · doi:10.1155/2012/916560 · Cited by 35
“Cord blood stem cells (CB-SCs) are a heterogeneous population composed of (i) very small embryonic-like stem cells, (ii) mesenchymal stem cells (MSCs), (iii) hematopoietic stem cells, and (iv) endothelial progenitor cells (EPCs) [63].”
BackgroundOhashi, W., Hattori, K., & Hattori, Y. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225540 · Cited by 36
Mandrup-Poulsen, T. R. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.04.006 · Cited by 34
Self-citationTargeting neuroinflammation in distal symmetrical polyneuropathy in diabetes
Chong, Z. Z., Menkes, D. L., & Souayah, N. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104087 · Cited by 31
Tseng, H. H. L., Vong, C. T., Kwan, Y. W., Lee, S. M., & Hoi, M. P. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01161 · Cited by 30
Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells
Jo, S., & Fang, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.716692 · Cited by 35
“Anakinra IL-1 receptor antagonist Phase II, NCT00303394 Reduction of glycated hemoglobin level and enhanced secretion of C peptide (116)”
BackgroundMechanistic and therapeutic links between rheumatoid arthritis and diabetes mellitus
Li, J., Chen, Y., Liu, Q., Tian, Z., & Zhang, Y. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00816-1 · Cited by 39
Anti-Inflammatory Effects of Melatonin in Rats with Induced Type 2 Diabetes Mellitus
Yapışlar, H., Hacıosmanoğlu, E., Sarıoğlu, T., Değirmencioğlu, S., Söğüt, İ., Poteser, M., & Ekmekçioğlu, C. (2022) · Life · doi:10.3390/life12040574 · Cited by 36
Powers, N. E., Swartzwelter, B. J., Marchetti, C., de Graaf, D. M., Lerchner, A., Schlapschy, M., Datar, R., Binder, U., Edwards, C. K., Skerra, A., et al. (2020) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)49941-8 · Cited by 30
Pulling down the plug on atherosclerosis: Cooling down the inflammasome
Hansson, G. K., & Klareskog, L. (2011) · Nature Medicine · doi:10.1038/nm0711-790 · Cited by 32
The mechanisms linking adiposopathy to type 2 diabetes
Yang, J., Kang, J., & Guan, Y. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0288-9 · Cited by 33
“A 13-week treatment of type 2 diabetic patients with anakinra, a recombinant human interleukin-1 receptor antagonist, also attenuates hyperglycemia and improves islet insulin secretion dysfunction [49].”
BackgroundChang, C. C., & Bachove, I. (2014) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s46017 · Cited by 32
Therapeutic Targets for Management of Periodontitis and Diabetes
Sima, C., & Dyke, T. E. V. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160216150338 · Cited by 34
Nicholas, D., Andrieu, G. P., Strissel, K. J., Nikolajczyk, B. S., & Denis, G. V. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2320-0 · Cited by 35
Interorgan Crosstalk Contributing toβ-Cell Dysfunction
Tanabe, K., Amo-Shiinoki, K., Hatanaka, M., & Tanizawa, Y. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3605178 · Cited by 33
Herder, C., Kannenberg, J. M., Carstensen‐Kirberg, M., Huth, C., Meisinger, C., Köenig, W., Peters, A., Rathmann, W., Roden, M., & Thorand, B. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0498-6 · Cited by 30
Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals
Urwyler, S. A., Schuetz, P., Ebrahimi, F., Donath, M. Y., & Christ-Crain, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3931 · Cited by 29
Self-citationDo flavanols-rich natural products relieve obesity-related insulin resistance?
Engin, A. B., Tsatsakis, A. M., Tsoukalas, D., & Engin, A. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.12.055 · Cited by 31
Hong, S., Lee, J., Cho, J. H., Kwon, H., Park, S. E., Rhee, E., Park, C., Oh, K. W., Park, S., & Lee, W. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.1.105 · Cited by 34
Ghiasi, S. M., Dahllöf, M. S., Osmai, Y., Osmai, M., Jakobsen, K. K., Aivazidis, A., Tyrberg, B., Perruzza, L., Prause, M. C. B., Christensen, D. P., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.08.001 · Cited by 32
Self-citationRyden, A., Štechová, K., Durilová, M., & Faresjö, M. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.958 · Cited by 31
O’Rourke, R. W. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0067-6 · Cited by 32
“Therapy directed at other cytokines also demonstrates potential: Treatment with a recombinant IL-1-receptor antagonist ameliorates diabetes in humans [ 67 ] and represents an early step toward cytokine- and adipokine-based pharmacotherapy.”
Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes
Li, H., Liu, T., Shi, X., Du, H., Cai, C., Yang, D., Qu, L., Dou, H., Jiao, B., & Jiao, B. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118164 · Cited by 32
Ardestani, A. D., Sauter, N. S., Paroni, F., Dharmadhikari, G., Cho, J., Lupi, R., Marchetti, P., Oberholzer, J., Kerr-Conte, J., & Maedler, K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.210526 · Cited by 36
RetractedShapira, N. (2019) · Nutrients · doi:10.3390/nu11102373 · Cited by 35
Gaetano, A. D., & Hardy, T. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222833 · Cited by 30
“[13] used our previously published model [10] as a basis for focusing on the effect of IL-1β (Inter-Leukin -1 β) inhibitors such as anakinra [15, 16].”
BackgroundMethodRoesti, E. S., Boyle, C. N., Zeman, D. T., Sande-Melón, M., Storni, F., Cabral‐Miranda, G., Knuth, A. K., Lutz, T. A., Vogel, M. T., & Bachmann, M. F. (2020) · Vaccines · doi:10.3390/vaccines8010116 · Cited by 30
“Interventions directed against the major pro-inflammatory players have shown some success in mouse models and clinical trials [15,18,19], but to date there is no disease-modifying drug available that directly targets islet amyloid and its associated complications.”
BackgroundImmune regulation of islet homeostasis and adaptation
Guo, J., & Fu, W. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa009 · Cited by 33
The role of P2X7 receptor in infection and metabolism: Based on inflammation and immunity
Cai, X. T., Yao, Y., Teng, F., Li, Y., Wu, L., Yan, W., & Lin, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108297 · Cited by 34
Exercise as a Moderator of Persistent Neuroendocrine Symptoms of COVID-19
Rebello, C. J., Axelrod, C. L., Reynolds, C. F., Greenway, F. L., & Kirwan, J. P. (2022) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000284 · Cited by 32
Xia, Y., Zhang, Q., Ye, Y., Wu, X., He, F., Peng, Y., Yin, Y., & Ren, W. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.716 · Cited by 29
Wang, M., Liu, J., Zhang, Z., Zhang, H., Wang, N., Chen, X., Han, X., Lü, Q., & Chi, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.846591 · Cited by 34
“Although we did not find that dietary intervention could significantly reduce the level of the pro-inflammatory cytokine IL-1β, the anti-IL-1β agents improve insulin secretion and β cell function and reduce inflammation in humans (30).”
BackgroundNoureldein, M. H., Nawfal, R., Bitar, S., Maxwell, S., Khurana, I., Kassouf, H. K., Khuri, F. R., El‐Osta, A., & Eid, A. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04485-x · Cited by 31
Chen, P., Pan, K., Song, N., Yang, Y., Gu, C., Zhong, P., Li, L., Li, M., Zhang, Y., Dai, Z., et al. (2022) · Matter · doi:10.1016/j.matt.2022.12.002 · Cited by 30
Role of immune system modulation in prevention of type 1 diabetes mellitus
Hassan, G. A., Sliem, H. A., Ellethy, A. T., & Salama, M.-S. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.102989 · Cited by 30
Translational Control of Inducible Nitric Oxide Synthase by p38 MAPK in Islet β-Cells
Nishiki, Y., Adewola, A. F., Hatanaka, M., Templin, A. T., Maier, B., & Mirmira, R. G. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1230 · Cited by 30
Weaver, J. R., Nadler, J. L., & Taylor, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142735 · Cited by 32
Ding, L., Yuan, X., Yan, J., Huang, Y., Xu, M., Yang, Z. L., Yang, N., Wang, M., Zhang, C., & Zhang, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.023 · Cited by 29
Sun, Y., Zhou, S., Shi, Y., Zhou, Y., Zhang, Y., Liu, K., Zhu, Y., & Han, X. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154335 · Cited by 29
A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Tilg, H., Effenberger, M., & Adolph, T. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1681397 · Cited by 28
The role of pyroptosis in metabolism and metabolic disease
Zheng, Z., Yang, S., Dai, W., Xue, P., Sun, Y., Wang, J., Zhang, X., Jiang, L., & Kong, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116863 · Cited by 32
Hanefeld, M. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000225 · Cited by 28
Kousathana, F., Georgitsi, M., Lambadiari, V., Giamarellos‐Bourboulis, E. J., Dimitriadis, G., & Mouktaroudi, M. (2016) · Cytokine · doi:10.1016/j.cyto.2016.11.009 · Cited by 28
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 50
A Positive Causal Influence of IL-18 Levels on the Risk of T2DM: A Mendelian Randomization Study
Zhuang, H., Han, J., Cheng, L., & Liu, S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00295 · Cited by 29
Rasoulinejad, S. A., Karkhah, A., Paniri, A., Saleki, K., Pirzadeh, M., & Nouri, H. R. (2020) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2020.1808986 · Cited by 30
Dimosiari, A., Patoulias, D., Kitas, G. D., & Dimitroulas, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041302 · Cited by 29
da Costa, J. A. C., & Ikizler, T. A. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00664.x · Cited by 30
Dampening insulin signaling by an NLRP3 'meta-flammasome'
Choi, A. M. K., & Nakahira, K. (2011) · Nature Immunology · doi:10.1038/ni.2028 · Cited by 28
Obesity and cancer: at the crossroads of cellular metabolism and proliferation
O’Rourke, R. W. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.08.012 · Cited by 35
Nonsaponin fractions of Korean Red Ginseng extracts prime activation of NLRP3 inflammasome
Han, B.-C., Ahn, H., Lee, J., Jeon, E., Seo, S., Jang, K. H., Lee, S., Kim, C. H., & Lee, G. (2016) · Journal of Ginseng Research · doi:10.1016/j.jgr.2016.10.001 · Cited by 29
Conti, P., Ronconi, G., Kritas, S. K., Caraffa, A., & Theoharides, T. C. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.01.008 · Cited by 29
Role of innate immune cells in metabolism: from physiology to type 2 diabetes
Dalmas, É. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00736-5 · Cited by 30
Liu, W., Yin, Y., Wang, M., Fan, T., Zhu, Y., Shen, L., Peng, S., Gao, J., Deng, G., Meng, X., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011840 · Cited by 30
“The abbreviations used are: cSHP2-KO, conditional SHP2 knockout; SHP2, Src homology 2 domain-containing tyrosine phosphatase-2; T2D, type 2 diabetes; NAFLD, nonalcoholic fatty liver disease; NCD, normal chow diet; HFD, high-fat diet; DKO, double knockout; NLRP3, Nod-like receptor family protein 3; IPGTT, intraperitone…”
BackgroundInfluentialVascular Complications of Diabetes Mellitus
Chiong, Y., & Evans‐Molina, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_49 · Cited by 31
Modulation of Inflammasome Activity for the Treatment of Auto-inflammatory Disorders
Naik, E., & Dixit, V. M. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9383-8 · Cited by 28
The Role of Immunomodulation Therapy in Autoimmune Diabetes
Ludvigsson, J. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300213 · Cited by 32
Does Glycemic Control Modulate the Impairment of NLRP3 Inflammasome Activation in Type 2 Diabetes?
Iannantuoni, F., Díaz‐Morales, N., Escribano‐López, I., Solá, E., Torres, I. R., Apostolova, N., Bañuls, C., Rovira‐Llopis, S., Rocha, M., & Víctor, V. M. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7582 · Cited by 28
The Role of Neuroinflammation in the Comorbidity of Psychiatric Disorders and Internal Diseases
Cătălina, G. R., Gheorman, V., Gheorman, V., & Forțofoiu, M.-C. (2025) · Healthcare · doi:10.3390/healthcare13070837 · Cited by 32
“Studies have shown that IL-1 β receptor antagonists, such as anakinra, significantly improve beta-cell function and glycemic control in patients with type 2 diabetes [122].”
Kinnunen, K., Piippo, N., Loukovaara, S., Hytti, M., Kaarniranta, K., & Kauppinen, A. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0396-4 · Cited by 29
Jin, W. L., Cui, B., Li, P., Hua, F., Lv, X., Zhou, J., Hu, Z., & Zhang, X. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.001 · Cited by 30
Glycemic reduction alters white blood cell counts and inflammatory gene expression in diabetes
Fang, X., Dorcely, B., Ding, X.-P., Yin, S., Son, N.-H., Hu, S., & Goldberg, I. J. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.08.003 · Cited by 27
Altered islet prohormone processing: a cause or consequence of diabetes?
Ramzy, A., & Kieffer, T. J. (2021) · Physiological Reviews · doi:10.1152/physrev.00008.2021 · Cited by 32
Deng, J., Fukushima, Y., Nozaki, K., Nakanishi, H., Yada, E., Terai, Y., Fueki, K., & Itaka, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091785 · Cited by 29
Parasympathetic tonus in type 2 diabetes and pre-diabetes and its clinical implications
Hadad, R., Akobe, S. F., Weber, P., Madsen, C. V., Larsen, B. S., Madsbad, S., Nielsen, O. W., Domínguez, H., Haugaard, S. B., & Sajadieh, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-22675-2 · Cited by 27
Andersson‐Assarsson, J. C., van Deuren, R. C., Kristensson, F. M., Steehouwer, M., Sjöholm, K., Svensson, P., Pieterse, M., Gilissen, C., Taube, M., Jacobson, P., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104621 · Cited by 28
Links between oral microbiome and insulin resistance: Involvement of MAP kinase signaling pathway
Chang, Y., Cheng, W., Hsiao, Y.-C., Su, G.-W., Lin, S.-J., Wei, Y., Chou, H., Lin, H.-P. P., Lin, G.-Y., & Chan, H. (2023) · Biochimie · doi:10.1016/j.biochi.2023.06.013 · Cited by 27
Vagal pathways for systemic regulation of glucose metabolism
Borgmann, D., & Fenselau, H. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.07.010 · Cited by 30
Urizar, A. I., Friberg, J., Christensen, D. P., Christensen, G. L., & Billestrup, N. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0199 · Cited by 28
Immune cells and metabolic dysfunction
Eheim, A. L., Medříková, D., & Herzig, S. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0403-7 · Cited by 28
The Bidirectional Relationship between Metabolism and Immune Responses
Raval, F., & Nikolajczyk, B. S. (2013) · Discoveries · doi:10.15190/d.2013.6 · Cited by 30
Misaki, Y., Miyauchi, R., Mochizuki, K., Takabe, S., Shimada, M., Ichikawa, Y., & Goda, T. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.011 · Cited by 28
Neutralizing Th2 Inflammation in Neonatal Islets Prevents β-Cell Failure in Adult IUGR Rats
Santos, L. J. J., Li, C., Doulias, P., Ischiropoulos, H., Worthen, G. S., & Simmons, R. A. (2014) · Diabetes · doi:10.2337/db13-1226 · Cited by 29
Toprak, H., Yetiş, H., Alkan, A., Filiz, M., Kurtcan, S., Aralaşmak, A., Aksu, M. Ş., & Cesur, Y. (2016) · British Journal of Radiology · doi:10.1259/bjr.20150680 · Cited by 29
Alcarraz‐Vizán, G., Castaño, C., Visa, M., Montané, J., Servitja, J., & Novials, A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2505-1 · Cited by 27
Doody, N. E., Dowejko, M., Akam, E. C., Cox, N. J., Bhatti, J. S., Singh, P., & Mastana, S. S. (2017) · Annals of Human Genetics · doi:10.1111/ahg.12197 · Cited by 27
Sokolova, M., Ranheim, T., Louwe, M. C., Halvorsen, B. L., Yndestad, A., & Aukrust, P. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000704 · Cited by 28
Böni‐Schnetzler, M., & Donath, M. Y. (2011) · Cell Research · doi:10.1038/cr.2011.85 · Cited by 27
Self-citationLiu, L., Wan, X., Liu, J., Huang, Z., Cao, X., & Li, Y. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0055 · Cited by 28
Can Treating Persistent Inflammation Limit Protein Energy Wasting?
Stenvinkel, P. (2012) · Seminars in Dialysis · doi:10.1111/sdi.12020 · Cited by 26
Modeling Diabetes Disease Progression and Salsalate Intervention in Goto-Kakizaki Rats
Cao, Y., DuBois, D. C., Sun, H., Almon, R. R., & Jusko, W. J. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185686 · Cited by 27
Santalahti, K., Maksimow, M., Airola, A., Pahikkala, T., Hutri‐Kähönen, N., Jalkanen, S., Raitakari, O. T., & Salmi, M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2081 · Cited by 29
Ursini, F., Russo, E., Ruscitti, P., Giacomelli, R., & Sarro, G. D. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.030 · Cited by 26
Dapueto, R., Rodriguez‐Duarte, J., Galliussi, G., Kamaid, A., Bresque, M., Batthyány, C., López, G. V., & Escande, C. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101833 · Cited by 29
“Moreover, it has been shown that the blockade of IL-1β using a recombinant human IL-1 receptor antagonist (Anakinra) in clinical trials ameliorates type II diabetes and systemic inflammation [46].”
BackgroundInteractions between islets and regulatory immune cells in health and type 1 diabetes
Budd, M. A., Monajemi, M., Colpitts, S. J., Crome, S. Q., Verchere, C. B., & Levings, M. K. (2021) · Diabetologia · doi:10.1007/s00125-021-05565-6 · Cited by 27
Jiao, J., Wang, Z., Guo, Y., Liu, J., Huang, X., Ni, X., Gao, D., Sun, L., Zhu, X., Zhou, Q., et al. (2021) · PeerJ · doi:10.7717/peerj.12384 · Cited by 28
“suggested that blocking IL-1β is a potential therapy in the treatment of T2DM (Larsen et al., 2007).”
BackgroundRheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association
Muzio, C. D., Cipriani, P., & Ruscitti, P. (2022) · BioDrugs · doi:10.1007/s40259-022-00561-7 · Cited by 28
NOD-like Receptors—Emerging Links to Obesity and Associated Morbidities
Bauer, S., Hezinger, L., Rexhepi, F., Ramanathan, S., & Kufer, T. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108595 · Cited by 28
“Antibodies against IL-1 β (canakinumab, gevokizumab, LY2189) and IL-1 receptor antagonists (anakinra) represent potential therapeutics for T2DM and atherosclerosis and have already been tested successfully in human studies [85,181,249–253].”
BackgroundChen, W. K., Cui, W., Wu, J., Zheng, W., Sun, X., Zhang, J., Shang, H., Yuan, Y., Li, X., Wang, J., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155641 · Cited by 28
Maternal Immunization Affects In Utero Programming of Insulin Resistance and Type 2 Diabetes
Eberle, C., Merki, E., Yamashita, T., Johnson, S., Armando, A. M., Quehenberger, O., Claudio Napoli, A., & Palinski, W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045361 · Cited by 26
Interactions between differential fatty acids and inflammatory stressors—impact on metabolic health
Murphy, A. M., Lyons, C. L., Finucane, O. M., & Roche, H. M. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.05.003 · Cited by 27
Tanioka, T., Tamura, Y., Fukaya, M., Shinozaki, S., Mao, J., Kim, M., Shimizu, N., Kitamura, T., & Kaneki, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.192732 · Cited by 29
Role of Innate Immunity in the Pathogenesis of Type 1 and Type 2 Diabetes
Lee, M. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.8.1038 · Cited by 30
Giannulis, I., Mondini, E., Cinti, F., Frontini, A., Murano, I., Barazzoni, R., Barbatelli, G., Accili, D., & Cinti, S. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.09.006 · Cited by 30
American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden, Z. T. (2008) · Diabetes Care · doi:10.2337/dc08-zb11 · Cited by 26
Immunotherapy of type 1 diabetes — How to rationally prioritize combination therapies in T1D
Boettler, T., & von Herrath, M. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.07.008 · Cited by 26
“IL1 has been reported to cause β-cell dysfunction [19]; consequently therapeutic IL1 receptor blockade has been successfully performed in humans with type 2 diabetes [20].”
Background
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.